These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24218996)

  • 21. Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.
    Yeni P; Mills A; Peeters M; Vingerhoets J; Kakuda TN; De Smedt G; Woodfall B
    Curr HIV Res; 2010 Oct; 8(7):564-76. PubMed ID: 20946097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etravirine.
    Deeks ED; Keating GM
    Drugs; 2008; 68(16):2357-72. PubMed ID: 18973398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
    Ghosn J; Chaix ML; Delaugerre C
    AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor.
    James C; Preininger L; Sweet M
    Am J Health Syst Pharm; 2012 May; 69(10):857-61. PubMed ID: 22555080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors].
    Bonora S; Calcagno A; Gonzalez de Requena D; Bargiacchi O; Di Perri G
    Infez Med; 2006 Jun; 14(2):61-70. PubMed ID: 16891850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mechanism of action and pharmacokinetics of rilpivirine].
    Portilla J; Estrada V
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():2-5. PubMed ID: 24252527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
    Fulco PP; McNicholl IR
    Pharmacotherapy; 2009 Mar; 29(3):281-94. PubMed ID: 19249947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.
    Adams J; Patel N; Mankaryous N; Tadros M; Miller CD
    Ann Pharmacother; 2010 Jan; 44(1):157-65. PubMed ID: 19996323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding the reverse transcriptase inhibitors in HIV.
    Edmonds-Ogbuokiri J
    Fac Notes (New Orleans La); 1998; 10(6):13-5. PubMed ID: 11366142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
    Darwich L; Esteve A; Ruiz L; Bellido R; Clotet B; Martinez-Picado J
    Antivir Ther; 2008; 13(7):945-51. PubMed ID: 19043929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?
    Dahri K; Ensom MH
    Clin Pharmacokinet; 2007; 46(2):109-32. PubMed ID: 17253884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
    Moyle G
    Drugs; 2001; 61(1):19-26. PubMed ID: 11217868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
    Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
    Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
    Torre D; Tambini R; Speranza F
    HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
    Lambert-Niclot S; Charpentier C; Storto A; Fofana D; Soulie C; Fourati S; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG
    J Antimicrob Chemother; 2014 Apr; 69(4):1086-9. PubMed ID: 24302653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
    De Clercq E
    Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IDX-899, an aryl phosphinate-indole non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection.
    Klibanov OM; Kaczor RL
    Curr Opin Investig Drugs; 2010 Feb; 11(2):237-45. PubMed ID: 20112173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.